SEC Form 4 · accession 0001209191-16-153187
EAGLE PHARMACEUTICALS, INC. · EGRX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Steven L. Krill
Officer — EVP & Chief Scientific Officer
Period of report
Nov 23, 2016
Accepted (ET)
Dec 2, 2016 · 8:56 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000827871
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Nov 23, 2016 | M | 200 | $8.78 | A | 200 | D | |
| Common Stock | Nov 23, 2016 | S | 200 | $80.00 | D | 0 | D | |
| Common Stock | Nov 30, 2016 | M | 1,950 | $8.78 | A | 1,950 | D | |
| Common Stock | Nov 30, 2016 | S | 1,950 | $80.00 | D | 0 | D | |
| Common Stock | Nov 30, 2016 | M | 2,530 | $8.78 | A | 2,530 | D | |
| Common Stock | Nov 30, 2016 | S | 2,530 | $80.00 | D | 0 | D | |
| Common Stock | Nov 30, 2016 | M | 1,307 | $4.42 | A | 1,307 | D | |
| Common Stock | Nov 30, 2016 | S | 1,307 | $80.00 | D | 0 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F1 | $8.78 | Nov 23, 2016 | M | 200 | D | — | Jul 11, 2022 | Common Stock | 200 | 2,530 | D |
| Stock Option (right to buy)F2 | $8.78 | Nov 30, 2016 | M | 1,950 | D | — | Sep 25, 2021 | Common Stock | 1,950 | 0 | D |
| Stock Option (right to buy)F1 | $8.78 | Nov 30, 2016 | M | 2,530 | D | — | Jul 11, 2022 | Common Stock | 2,530 | 0 | D |
| Stock Option (right to buy)F3 | $4.42 | Nov 30, 2016 | M | 1,307 | D | — | Apr 18, 2023 | Common Stock | 1,307 | 19,210 | D |
Explanation of responses
- F125% of the shares subject to the option vested on July 12, 2013 and the remainder vested in equal monthly installments over a period of three years.
- F225% of the shares subject to the option vested on September 26, 2012 and the remainder vested in equal monthly installments over a period of three years.
- F325% of the shares subject to the option vested on April 19, 2014 and the remainder shall vest in equal monthly installments over a period of three years.